Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shingo Nakayamada & Yoshiya Tanaka. (2023) Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?. Expert Opinion on Investigational Drugs 32:10, pages 901-908.
Read now
Read now
Yoshiya Tanaka & Hiroyuki Izutsu. (2020) Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opinion on Pharmacotherapy 21:9, pages 1015-1025.
Read now
Read now
Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka. (2019) Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Review of Clinical Immunology 15:7, pages 693-700.
Read now
Read now
Roy Fleischmann. (2017) A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. Expert Opinion on Pharmacotherapy 18:14, pages 1525-1533.
Read now
Read now
Articles from other publishers (17)
Sajad Dehnavi, Mahvash Sadeghi, Jalil Tavakol Afshari & Mojgan Mohammadi. (2023) Interactions of mesenchymal stromal/stem cells and immune cells following MSC-based therapeutic approaches in rheumatoid arthritis. Cellular Immunology 393-394, pages 104771.
Crossref
Crossref
Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis
through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Crossref
Qipeng Zhan, Jianan Zhang, Yubin Lin, Wenjing Chen, Xinzou Fan & Dunfang Zhang. (2023) Pathogenesis and treatment of Sjogren’s syndrome: Review and update. Frontiers in Immunology 14.
Crossref
Crossref
Ziteng Wang & Eric Chun Yong Chan. (2022) Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics. Clinical Pharmacology & Therapeutics 112:2, pages 291-296.
Crossref
Crossref
Ting-Hui Chang, Chien-Sheng Wu, Shih-Hwa Chiou, Chih-Hung Chang & Hsiu-Jung Liao. (2022) Adipose-Derived Stem Cell Exosomes as a Novel Anti-Inflammatory Agent and the Current Therapeutic Targets for Rheumatoid Arthritis. Biomedicines 10:7, pages 1725.
Crossref
Crossref
Shuang Liu, Hongxing Ma, Huaxi Zhang, Chengjie Deng & Ping Xin. (2021) Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clinical Immunology 230, pages 108793.
Crossref
Crossref
Qingqing Xiao, Xiaotong Li, Yi Li, Zhenfeng Wu, Chenjie Xu, Zhongjian Chen & Wei He. (2021) Biological drug and drug delivery-mediated immunotherapy. Acta Pharmaceutica Sinica B 11:4, pages 941-960.
Crossref
Crossref
Anna Ravn Landtblom, Therese M-L Andersson, Paul W Dickman, Karin E Smedby, Sandra Eloranta, Nurgul Batyrbekova, Jan Samuelsson, Magnus Björkholm & Malin Hultcrantz. (2020) Risk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patients. Leukemia 35:2, pages 476-484.
Crossref
Crossref
Yuyi Zhou, Chunfang Sun & Chunyan Chen. (2021) The optimal dosage of pefcitinib for the treatment of active rheumatoid arthritis. Medicine 100:7, pages e24586.
Crossref
Crossref
Seunghyun Lee, Shingo Nakayamada, Satoshi Kubo, Kaoru Yamagata, Hiroko Yoshinari & Yoshiya Tanaka. (2020) Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. Rheumatology 59:10, pages 3058-3069.
Crossref
Crossref
Yukihiro Kitanaga, Emiko Imamura, Yutaka Nakahara, Hidehiko Fukahori, Yasutomo Fujii, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka. (2020) In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology 59:8, pages 1957-1968.
Crossref
Crossref
Walid Fakhouri, Xiaofei Wang, Immaculate de la Torre & Claudia Nicolay. (2020) A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate. Journal of Health Economics and Outcomes Research, pages 10-23.
Crossref
Crossref
Ping Xin, Xiaoyun Xu, Chengjie Deng, Shuang Liu, Youzhi Wang, Xuegang Zhou, Hongxing Ma, Donghua Wei & Shiqin Sun. (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology 80, pages 106210.
Crossref
Crossref
Anja Dullius, Claudia Monfroni Rocha, Stefan Laufer, Claucia Fernanda Volken de Souza & Márcia Inês Goettert. (2019) Are peptides a solution for the treatment of hyperactivated JAK3 pathways?. Inflammopharmacology 27:3, pages 433-452.
Crossref
Crossref
Yoshiya Tanaka. 2019. Mosaic of Autoimmunity. Mosaic of Autoimmunity
629
637
.
Doreen E Szollosi, Mohammed K Manzoor, Andrea Aquilato, Patricia Jackson, Ola M Ghoneim & Ivan O Edafiogho. (2018) Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases. Journal of Pharmacy and Pharmacology 70:1, pages 18-26.
Crossref
Crossref
Taher E. Taher, Jonas Bystrom, Voon H. Ong, David A. Isenberg, Yves Renaudineau, David J. Abraham & Rizgar A. Mageed. (2017) Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. Clinical Reviews in Allergy & Immunology 53:2, pages 237-264.
Crossref
Crossref